Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) were trading largely flat post-market Monday after the biotech company released its Q4 earnings report and issued 2025 guidance that was largely in ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Stocks started rising as the day unfolded with Fed Chair Jerome Powell reinforcing that interest rates remain in a "good ...

Stocks are marking daily gains, but it's nothing to write home about as investors await an update on tariffs while readying ...

After hours: February 12 at 4:01:44 PM EST Loading Chart for TTSH ...

This release updates cesium-native from v0.44.1 to v0.44.2. See the changelog for a complete list of changes in cesium-native. This release updates cesium-native from v0.44.0 to v0.44.1. See the ...

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

After hours: 7:04:28 p.m. EST ...